MX2021004551A - Composicion farmaceutica para el tratamiento de la anemia aplasica. - Google Patents

Composicion farmaceutica para el tratamiento de la anemia aplasica.

Info

Publication number
MX2021004551A
MX2021004551A MX2021004551A MX2021004551A MX2021004551A MX 2021004551 A MX2021004551 A MX 2021004551A MX 2021004551 A MX2021004551 A MX 2021004551A MX 2021004551 A MX2021004551 A MX 2021004551A MX 2021004551 A MX2021004551 A MX 2021004551A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
week
aplastic anemia
treating aplastic
î1⁄4g
Prior art date
Application number
MX2021004551A
Other languages
English (en)
Inventor
Yukie Tsuji
Miyako KODAMA
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of MX2021004551A publication Critical patent/MX2021004551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para el tratamiento de la anemia aplásica, que comprende Romiplostim como ingrediente activo, en la que la composición farmacéutica se administra por vía subcutánea una vez a la semana, en donde Romiplostim se administra a 10 µg/kg/semana durante 4 semanas desde el inicio de la administración, administrándose a más de 10 µg/kg/semana y a un máximo de 20 µg/kg/semana después de la quinta semana.
MX2021004551A 2018-10-26 2019-10-25 Composicion farmaceutica para el tratamiento de la anemia aplasica. MX2021004551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018202097 2018-10-26
PCT/JP2019/041814 WO2020085467A1 (ja) 2018-10-26 2019-10-25 再生不良性貧血を治療するための医薬組成物

Publications (1)

Publication Number Publication Date
MX2021004551A true MX2021004551A (es) 2021-07-16

Family

ID=70332110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004551A MX2021004551A (es) 2018-10-26 2019-10-25 Composicion farmaceutica para el tratamiento de la anemia aplasica.

Country Status (16)

Country Link
US (1) US20210379154A1 (es)
EP (1) EP3881856A4 (es)
JP (1) JPWO2020085467A1 (es)
KR (1) KR20210087045A (es)
CN (1) CN112888453A (es)
AU (1) AU2019364063A1 (es)
BR (1) BR112021007710A2 (es)
CA (1) CA3117477A1 (es)
EA (1) EA202191130A1 (es)
IL (1) IL282470A (es)
MA (1) MA53189B2 (es)
MX (1) MX2021004551A (es)
SG (1) SG11202104199WA (es)
TW (1) TW202021611A (es)
WO (1) WO2020085467A1 (es)
ZA (1) ZA202102940B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114027263A (zh) * 2021-12-01 2022-02-11 上海中医药大学 一种获得性再生障碍性贫血模型小鼠的生产方法
TW202341992A (zh) * 2022-02-02 2023-11-01 國立大學法人筑波大學 用於臍帶血移植後之血球恢復之醫藥組合物
WO2024028744A1 (en) * 2022-08-01 2024-02-08 Zydus Lifesciences Limited Treatment for aplastic anemia (aa)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1124961B9 (en) * 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
JP6559185B2 (ja) 2017-06-09 2019-08-14 株式会社カプコン ゲームプログラムおよびゲーム装置

Also Published As

Publication number Publication date
MA53189A1 (fr) 2021-12-31
CA3117477A1 (en) 2020-04-30
BR112021007710A2 (pt) 2021-08-10
US20210379154A1 (en) 2021-12-09
JPWO2020085467A1 (ja) 2021-09-16
CN112888453A (zh) 2021-06-01
AU2019364063A1 (en) 2021-06-10
EP3881856A1 (en) 2021-09-22
EA202191130A1 (ru) 2021-07-22
MA53189B2 (fr) 2023-09-27
ZA202102940B (en) 2022-10-26
IL282470A (en) 2021-06-30
TW202021611A (zh) 2020-06-16
WO2020085467A1 (ja) 2020-04-30
SG11202104199WA (en) 2021-05-28
KR20210087045A (ko) 2021-07-09
EP3881856A4 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
MX2021008358A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
MX361590B (es) Suministro topico de composiciones para la piel que tienen ph bajo.
PH12020550341A1 (en) Niraparib formulations
MX2021006969A (es) Ligante peptidico.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
MX2017013141A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
MX2022006502A (es) Composiciones farmaceuticas.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2018008443A (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada.